✦ LIBER ✦

A multimodal approach to physical therapy in Parkinson's disease: Optimizing strategies

✍ Scribed by Tiago Mestre; Joaquim J. Ferreira; Samay Jain

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 302 KB
Volume: 24
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.22478

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neuroprotective therapy in Parkinson's d

Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis-targeted, disease-modifying strategy

✍ C. Warren Olanow; Joseph Jankovic 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 1 views

The introduction of levodopa in the late 1960s represented a landmark in the therapy of Parkinson's disease (PD). However, motor complications of chronic levodopa therapy have emerged as a major limitation of this otherwise effective therapy. Advancing medical and surgical treatment of these complic

Gene knockout approach to adenosine A2A

Gene knockout approach to adenosine A2A receptors in Parkinson's disease

✍ Jiang-Fan Chen; Michael A. Schwarzschild 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 281 KB

The power of cueing to circumvent dopami

The power of cueing to circumvent dopamine deficits: A review of physical therapy treatment of gait disturbances in Parkinson's disease

✍ Tamar C. Rubinstein; Nir Giladi; Jeffrey M. Hausdorff 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

Gait disturbances are among the primary symptoms of Parkinson's disease (PD) and contribute significantly to a patient's loss of function and independence. Standard treatment includes antiparkinsonian drugs, primarily levodopa. In addition to the standard drug regime, physical therapy is often presc

A double-blind, placebo-controlled study

A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease

✍ Barry J. Snow; Fiona L. Rolfe; Michelle M. Lockhart; Christopher M. Frampton; Jo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 1 views

## Abstract Multiple lines of evidence point to mitochondrial oxidative stress as a potential pathogenic cause for Parkinson's disease (PD). MitoQ is a powerful mitochondrial antioxidant. It is absorbed orally and concentrates within mitochondria where it has been shown to protect against oxidative

A data-driven approach to the study of h

A data-driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes

✍ Jacqueline M. Graham; Harvey J. Sagar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics

✍ C. Warren Olanow; Robert A. Hauser; Joseph Jankovic; William Langston; Anthony L 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 1 views

## Abstract A neuroprotective therapy is the single most important unmet medical need in Parkinson's disease. Several promising agents in the laboratory have been tested in the clinic, but none has been established in clinical trials to have a disease modifying effect despite positive results becau